LRRK2 and Parkinson disease: A better understanding of the potential effect of H1998 on the inhibition of different PD variants of LRRK2 will require combining in vitro assays with H1998 mutants in the context of an activated LRRK2, either by the removal of its N-terminal repeats or by more physiological means yet to be determined, with structural characterization of changes in the active site brought about by the combination of the PD and H1998 mutations.